Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Nephroblastoma Clinical Trial and Study.

- candidate number1125
- NTR NumberNTR58
- Date ISRCTN created4-aug-2005
- date ISRCTN requested28-jul-2005
- Date Registered NTR12-mrt-2005
- Secondary IDsN/A 
- Public TitleNephroblastoma Clinical Trial and Study.
- Scientific TitleNephroblastoma Clinical Trial and Study.
- hypothesisTo continue a risk-adapted stratification of therapeutic intensity, incorporating response to pre-operative chemotherapy, in all children with Wilms tumour and other renal tumours of childhood.
To test the treatment hypothesis that doxorubicin is not necessary in patients with intermediate risk tumours and local stage II or III by a multicentre prospective randomised trial.
To determine prospectively the prognostic significance of specific histological subtypes following pre-operative chemotherapy, as specified in the protocol. In particular, the study aims to: confirm the adverse prognostic significance of the blastemal predominant subtypes and whether this can be offset by intensifying therapy and investigate the hypothesis that the epithelial and stromal-predominant subtypes have a favourable prognosis and investigate the prognostic significance of the percentage necrosis after pre-operative chemotherapy in relation to the type and amount of residual viable tumour.
To minimise acute and late toxicity without jeopardising event free and overall survival by reducing treatment for: patients with focal anaplasia, and patients with stage I, intermediate risk tumours.
To determine prospectively the prognostic significance of tumour volume following pre-operative chemotherapy and its relation to histological subtype.
To determine prospectively the prognostic significance of specimen weight at time of nephrectomy and its relation to histological subtype.
To reduce the number of drug administrations, hospital visits and thereby costs in the preoperative phase.
- Healt Condition(s) or Problem(s) studiedNephroblastoma
- Inclusion criteria1. All localised disease nephroblastoma patients age more than 6 months or less than 18 years at time of diagnosis.
Unilateral tumour with clinical and ultrasonic characteristics compatible with nephroblastoma or biopsy proven histological diagnosis.
2. Written informed consent and national ethical committee approval.
3. Stage II and III intermediate risk histology after pre-treatment according to protocol and after operation.
- Exclusion criteria1. All other kind of renal tumours of infancy.
2. Patients without previous anti-tumour treatment.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlActive
- groupParallel
- Type-
- Studytypeintervention
- planned startdate 1-jun-2002
- planned closingdate1-jun-2009
- Target number of participants350
- InterventionsEstablishing equivalence between 2 post-operative treatments. Trialarm with Doxorubicine versus Trialarm without Doxorubicin.
- Primary outcomeEvent Free Survival (EFS).
- Secondary outcomeN/A
- Timepoints
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES SIOP Nephroblastoma Trial and Study Office
- Sponsor/Initiator Academic Medical Center (AMC), Emma Children's Hospital
- Funding
(Source(s) of Monetary or Material Support)
Stichting Kindergeneeskundig Kankeronderzoek (the Netherlands), Barncancerfonden (Sweden), Deutsche Krebshilfe (Germany)
- PublicationsN/A
- Brief summaryN/A
- Main changes (audit trail)
- RECORD26-jul-2005 - 6-dec-2006

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar